In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until disease progression or the participants are unable to tolerate the study drugs. 88 These preclinical studies offer paradigms for long term clinical trials in AML, https://abbv-744andotherbrd4inhib79134.blogdosaga.com/31879889/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled